This compound has been shown to efficiently inhibit LRRK2 in patients with PD (24), and the related molecule DNL151 (renamed BIIB122) has currently entered phase 2b clinical testing (clinicaltrials.gov). This evidence concerns the gene LRRK2 and Parkinson disease.